<DOC>
	<DOCNO>NCT03091673</DOCNO>
	<brief_summary>This sequential efficacy safety study pediatric patient type 1 diabetes . Subjects administer insulin induce low normal glycemic state receive age-appropriate dose G-Pen™ ( glucagon injection ) clinical research center ( CRC ) comparable setting .</brief_summary>
	<brief_title>Glucose Response G-Pen™ ( Glucagon Injection ) Pediatric T1D Patients</brief_title>
	<detailed_description>This open-label , Phase 3 sequential efficacy safety study pediatric patient age 2-17 type 1 diabetes . Patients complete screen procedure 30 day dose determine eligibility enrollment treatment phase . The procedure evaluate efficacy G-Pen™ ( glucagon injection ) consist induce low normal glycemic state administration insulin . Subjects age 2-11 give 0.5 mg dose G-Pen™ , subject ages 12-17 receive 1 mg dose G-Pen™ . Subjects age 12-17 return second visit 1-4 week later receive 0.5 mg dose G-Pen™ low normal glycemic stare . Plasma glucose glucagon level monitor 90 180 minute post-dosing , respectively , visit . A follow-up phone call safety check conduct 3 - 14 day follow administration final dose .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>diagnose T1D least 6 month Screening . current usage daily insulin treatment . pregnant nursing renal insufficiency hepatic synthetic insufficiency aspartate alanine aminotransferase &gt; 3 time upper limit normal hematocrit less equal 30 % use &gt; 2.0 U/kg total insulin dose per day inadequate venous access current seizure disorder history pheochromocytoma disorder increase risk pheochromocytoma history insulinoma history glycogen storage disease . active use alcohol drug abuse administration glucagon within 14 day first treatment visit participation study involve investigational drug device within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>